Bonesupport Holding Dirección

Dirección controles de criterios 3/4

El CEO de Bonesupport Holding's es Emil Billbäck , nombrado en Mar 2018, tiene una permanencia de 6.08 años. compensación anual total es SEK18.06M, compuesta por 29.7% salario y 70.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.52% de las acciones de la empresa, por valor de SEK84.35M. La antigüedad media del equipo directivo y de la junta directiva es de 4.9 años y 7.3 años, respectivamente.

Información clave

Emil Billbäck

Chief Executive Officer (CEO)

kr15.2m

Compensación total

Porcentaje del salario del CEO	41.7%
Permanencia del CEO	6.2yrs
Participación del CEO	0.7%
Permanencia media de la dirección	5yrs
Promedio de permanencia en la Junta Directiva	7.3yrs

Actualizaciones recientes de la dirección

Recent updates

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

Mar 16

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Nov 06

Bonesupport Holding AB (publ)'s (STO:BONEX) Path To Profitability

Mar 31

Insider Buying: The Bonesupport Holding AB (publ) (STO:BONEX) Chief Executive Officer Just Bought 4.0% More Shares

Mar 04

One Bonesupport Holding AB (publ) (STO:BONEX) Analyst Just Cut Their EPS Forecasts

Mar 02

What Kind Of Investors Own Most Of Bonesupport Holding AB (publ) (STO:BONEX)?

Feb 28

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Feb 07

Executive VP of R&D Michael Diefenbeck Just Bought 2.6% More Shares In Bonesupport Holding AB (publ) (STO:BONEX)

Jan 17

The Bonesupport Holding (STO:BONEX) Share Price Has Gained 283%, So Why Not Pay It Some Attention?

Dec 31

What Can We Make Of Bonesupport Holding's (STO:BONEX) CEO Compensation?

Dec 13

Analysts Expect Breakeven For Bonesupport Holding AB (publ) (STO:BONEX) Before Long

Nov 25

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Emil Billbäck en comparación con los beneficios de Bonesupport Holding?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	kr267m
Dec 31 2023	kr15m	kr6m	kr245m
Sep 30 2023	n/a	n/a	kr214m
Jun 30 2023	n/a	n/a	-kr30m
Mar 31 2023	n/a	n/a	-kr51m
Dec 31 2022	kr18m	kr5m	-kr68m
Sep 30 2022	n/a	n/a	-kr72m
Jun 30 2022	n/a	n/a	-kr71m
Mar 31 2022	n/a	n/a	-kr82m
Dec 31 2021	kr6m	kr4m	-kr86m
Sep 30 2021	n/a	n/a	-kr88m
Jun 30 2021	n/a	n/a	-kr96m
Mar 31 2021	n/a	n/a	-kr92m
Dec 31 2020	kr11m	kr6m	-kr101m
Sep 30 2020	n/a	n/a	-kr115m
Jun 30 2020	n/a	n/a	-kr127m
Mar 31 2020	n/a	n/a	-kr151m
Dec 31 2019	kr8m	kr5m	-kr161m
Sep 30 2019	n/a	n/a	-kr166m
Jun 30 2019	n/a	n/a	-kr191m
Mar 31 2019	n/a	n/a	-kr182m
Dec 31 2018	kr6m	kr4m	-kr176m

Compensación vs. Mercado: La compensación total de Emil($USD1.39M) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD790.88K).

Compensación vs. Ingresos: La compensación de Emil ha sido consistente con los resultados de la empresa en el último año.

CEO

Emil Billbäck (53 yo)

6.2yrs

Permanencia

kr15,176,000

Compensación

Mr. Emil Billbäck has been Chief Executive Officer at BONESUPPORT HOLDING AB (publ) since March 01, 2018. Mr. Billbäck is the Chief Executive Officer of BONESUPPORT AB. He has experience in the life scienc...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Emil Billbäck	Chief Executive Officer	6.2yrs	kr15.18m	0.69% SEK 105.0m
Håkan Johansson	Chief Financial Officer	5.5yrs	kr248.00k	0.084% SEK 12.7m
Michael Mortensen	Executive Vice President of Global R&D and Operations	2.4yrs	sin datos	0.020% SEK 3.0m
Annelie Vikner	Executive Vice President of Global Marketing	1.3yrs	sin datos	0.022% SEK 3.3m
Helena Brandt	Executive Vice President of Human Resources	6.6yrs	sin datos	0.026% SEK 3.9m
Michael Diefenbeck	Executive VP of Medical & Clinical Affairs and Chief Medical Officer	7.1yrs	sin datos	0.12% SEK 18.1m
Fergus MacLeod	GM & Executive VP of Commercial Operations of EUROW	4.5yrs	sin datos	0.036% SEK 5.5m
Michael Roth	GM & Executive VP of Commercial Operations of North America	3.9yrs	sin datos	0.030% SEK 4.6m

5.0yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BONEX es experimentado (5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Björn Odlander	Director	14.3yrs	kr302.00k	sin datos
Lennart Johansson	Independent Chairman of the Board	7.3yrs	kr2.94m	0.16% SEK 24.4m
Sven Bjorklund	Independent Director	7.4yrs	kr253.00k	sin datos
Christine Rankin	Independent Director	2yrs	kr756.00k	0.0030% SEK 453.9k
Mary O'Connor	Independent Director	2yrs	kr515.00k	0.038% SEK 5.7m

7.3yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de BONEX se considera experimentada (7.3 años de antigüedad promedio).

Bonesupport Holding Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Insider recently sold kr478k worth of stock

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Independent Director recently bought kr1.0m worth of stock

Independent Director recently bought kr1.1m worth of stock

Insider recently bought kr426k worth of stock

Insider recently sold kr701k worth of stock

Recent updates

Insider recently sold kr478k worth of stock

First quarter 2024 earnings released

Full year 2023 earnings: EPS exceeds analyst expectations

Price target increased by 14% to kr293

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 24%, revenue upgraded

Independent Director recently bought kr1.0m worth of stock

Bonesupport Holding AB Provides Sales Guidance for the Year 2024

Price target increased by 11% to kr179

Third quarter 2023 earnings released

Bonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone Infection

Independent Director recently bought kr1.1m worth of stock

Insider recently bought kr426k worth of stock

Second quarter 2023 earnings released: EPS: kr0.08 (vs kr0.25 loss in 2Q 2022)

BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open Fractures

Insider recently sold kr701k worth of stock

Forecast breakeven date moved forward to 2023

Chief Executive Officer recently sold kr15m worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold kr1.4m worth of stock

Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)

Price target increased by 17% to kr142

Bonesupport Holding AB (publ), Annual General Meeting, Nov 21, 2023

Director recently bought kr203k worth of stock

No independent directors

Bonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings released

No longer forecast to breakeven

Bonesupport's CERAMENT G Used in First U.S. Patient Cases

Forecast to breakeven in 2023

An unknown buyer acquired unknown minority stakes in Bonesupport Holding AB (publ) (OM:BONEX) from Helena Brandt for SEK 0.84 million.

Bonesupport Holding AB (publ) Announces Publication of Mid- to Long-Term Data Confirming the Sustained Clinical Effectiveness of CERAMENT G

Consensus forecasts updated

Second quarter 2022 earnings released: kr0.25 loss per share (vs kr0.42 loss in 2Q 2021)

Insider recently bought kr101k worth of stock

Forecast breakeven date moved forward to 2023

Price target increased to kr91.00

BONESUPPORT Receives Market Authorization for CERAMENT G in the US

Forecast breakeven date pushed back to 2024

Chairman of the Board recently bought kr1.2m worth of stock

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Bonesupport Holding AB (publ) to Report Fiscal Year 2021 Final Results on Apr 13, 2022

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

BONESUPPORT(TM) Announces Delays Within FDA Postpones CERAMENT G De Novo Decision

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Insider recently bought kr182k worth of stock

Third quarter 2021 earnings released

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Bonesupport Announces Supplementary US Denovo Application Submitted

Chief Executive Officer recently bought kr343k worth of stock

Price target decreased to kr65.00

Bonesupport Announces Study Results for its Investigational Device Exemption(IDE) Study, Fortify

Chief Financial Officer recently bought kr87k worth of stock

Insider recently bought kr401k worth of stock

Chairman of the board recently bought kr1.6m worth of stock

Second quarter 2021 earnings released

BONESUPPORTTM Receives Device Designation for CERAMENT G for the Indication Trauma

Chief Financial Officer recently bought kr210k worth of stock

Forecast to breakeven in 2023

Chief Financial Officer recently bought kr210k worth of stock

First quarter 2021 earnings released

Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019)

Bonesupport Holding AB (publ)'s (STO:BONEX) Path To Profitability